Clinical trials: Decompensated Liver Cirrhosis
Hepatitis B
Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver
This is a prospective, randomized, open-label clinical trial designed to compare the antiviral efficacy and safety of entecavir 0.5 mg once daily versus entecavir 1.0 mg once daily in adult patients with hepatitis B virus…
- Trial name
- NCT07816094
- Testing
- Entecavir
- Where
- Bangladesh
- Volunteers
- 48 people
- Sponsor
- Bangladesh Medical University
Decompensated Cirrhosis, AKI - Acute Kidney Injury
Study to Evaluate the Efficacy of Intravenous Administration of Human Albumin Versus Saline Solution in Patients With descompénsate Cirrhosis Grade 1B or Higher Renal Failure
This is a phase IV, unicentric, open-label. Patients eligible for this study will be patients with AKI 1B or greater and decompensated cirrhosis from the hospital participating in the study
- Trial name
- LIVER-AKI (NCT07270874)
- Testing
- Saline solution (NaCl 0.9%)
- Volunteers
- 114 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Liver Cirrhosis
Nurse Assisted Post-discharge Intervention in Decompensated Cirrhosis
In a randomized controlled trial, the effects of a nurse-driven post-discharge intervention for patients with liver cirrhosis compared with standard follow-up will be investigated.
- Trial name
- NurseAID (NCT04158986)
- Testing
- Nurse-driven post-discharge intervention
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Decompensated Liver Cirrhosis
TIPS in Patients With Decompensated Liver Cirrhosis
This is a single center patient registry of patients receiving a transjugular intrahepatic portosystemic shunt (TIPS) at Hannover Medical School.
- Trial name
- NCT04801290
- Testing
- TIPS insertion
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- Hannover Medical School
Cirrhosis, Liver, Portal Hypertension
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
This is a randomized single-blind feasibility trial to test the utilization of home blood pressure devices to improve the clinical management of decompensated cirrhosis patients.
- Conditions
- Cirrhosis, Liver, Portal Hypertension, Ascites Hepatic
- Trial name
- WATCH (NCT05928624)
- Testing
- Withings Home Blood Pressure Device and Scale, Standard of Care
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of California, San Francisco
Decompensated Cirrhosis
Evaluation of Low-dose Albumin and Midodrine Versus Midodrine Alone in Outcome of Recurrent Ascites in Patients With Decompensated Cirrhosis.
The project is about evaluation of albumin and midodrine versus midodrine alone in outcome of recurrent ascites in patients with decompensated cirrhosis. Cirrhosis occcurs in 50% of patients over 10 years.
- Trial name
- NCT06245590
- Testing
- Albumin, Midodrine, Standard of Care
- Where
- 2 sites in India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Caregivers
CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated Cirrhosis
The goal of this study is to enroll caretakers of patients with decompensated cirrhosis to determine if written emotional disclosure or resilience training interventions reduce distress and burden among primary informal…
- Trial name
- NCT04205396
- Testing
- Written emotional disclosure, Resilience training, No treatment
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Michigan
Cirrhosis, Liver, AKI
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI
- Trial name
- NCT03070353
- Testing
- Dextran 40
- Volunteers
- 10 people
- Sponsor
- Ramathibodi Hospital
Liver Cirrhosis
PiCCO Guided Therapy in Liver Cirrhosis
Prospective comparison of standard therapy in liver cirrhosis versus standard therapy plus intensified hemodynamic monitoring using the PiCCO system.
- Trial name
- NCT00232427
- Testing
- Hemodynamic monitoring system PiCCO
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Decompensated Cirrhosis
CirrhoCare in COVID-19: A Pilot, Remote, Home Monitoring Study in Advanced Cirrhosis
The COVID-19 outbreak has exposed many strengths and weaknesses of delivering healthcare, and we want to assess whether patients with advanced liver cirrhosis can be effectively monitored at home, to limit hospital visits and…
- Trial name
- NCT05045924
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Hypertension, Portal, Liver Cirrhosis
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis or other causes.
- Trial name
- NCT06082843
- Testing
- Avenciguat
- Where
- 15 sites in United States, Austria and 8 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Decompensated Liver Cirrhosis
An Follow-Up Study of Liver Cirrhosis
This is a follow-up study to assess safety and preliminary clinical activity of ADR-001 in patients with liver cirrhosis (Child-Pugh score; Grade B) caused by Hepatitis C or Nonalcoholic Steatohepatitis.
- Trial name
- NCT03472742
- Testing
- Mesenchymal Stem Cell
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Liver Cirrhosis, Alcoholic, Progression
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
A population based incidence cohort will enroll patients newly diagnosed with cirrhosis to investigate disease characteristics and outcomes, explore mechanisms predicting early death and hospital admission, and assess new…
- Conditions
- Liver Cirrhosis, Alcoholic, Progression, Liver Diseases, Decompensated Cirrhosis
- Trial name
- ProDoc (NCT04422223)
- Where
- Denmark
- Volunteers
- 550 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Liver Cirrhosis, Variceal Haemorrhage
Early Use of TIPSS in Patients With Cirrhosis and Variceal Bleeding
Gastro-oesophageal varices (swollen veins in the gullet and stomach) are present in 50% of patients with liver cirrhosis and are its most serious complication as their rupture results in potentially life threatening bleeding.
- Trial name
- EarlyTIPSS (NCT02377141)
- Testing
- Endoscopic Variceal Band Ligation, Transjugular Intrahepatic Porto-Systemic Stent Shunt
- Where
- 2 sites in United Kingdom
- Volunteers
- 59 people
- Sponsor
- University of Edinburgh
Hepatitis B, Decompensated Cirrhosis
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage).
- Trial name
- NCT05086536
- Testing
- no intervention
- Where
- 7 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Friendship Hospital
Cirrhosis, Liver
Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis
Spontaneous bacterial peritonitis (SBP) is a frequent and severe complication of cirrhotic patients with ascites.Early diagnosis and prompt treatment with effective antibiotics significantly improves the prognosis of this…
- Trial name
- NCT03695705
- Testing
- Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day
- Volunteers
- 142 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Cirrhosis
Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis
Disorders of glucose metabolism, such as impaired glucose intolerance (IGT) and diabetes mellitus (DM), frequently occur in cirrhosis. However, it has been underestimated when fasting plasma glucose (FPG) levels are considered.
- Trial name
- NCT04828512
- Volunteers
- 1,015 people
- Sponsor
- Yonsei University
Chronic Hepatitis C
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
The primary objective of this program is to provide DCV for 24 weeks to be given in combination with SOF to subjects with chronic hepatitis C with decompensated cirrhosis or post-liver transplant subjects with chronic hepatitis C…
- Trial name
- NCT02161939
- Testing
- Daclatasvir (BMS-790052), Sofosbuvir
- Where
- 20 sites in United States
- Sponsor
- Bristol-Myers Squibb
Decompensated Cirrhosis
To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.
All consecutive patients admitted in ILBS from MAY 2015 to DECEMBER 2016. Decompensated cirrhosis patients will be randomized into Group 1: MVP (Moderate Volume Paracentesis) of less than 5 litres with iv albumin at a dose 8…
- Trial name
- NCT02467322
- Testing
- Albumin, ascitic fluid
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Institute of Liver and Biliary Sciences, India